These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 28951471)

  • 1. Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus.
    Li Z; Wang D; Gu Y; Song S; He M; Shi J; Liu X; Wei S; Li J; Yu H; Zheng Q; Yan X; Baker TS; Zhang J; McLellan JS; Li S; Xia N
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
    Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33.
    Roth SD; Sapp M; Streeck RE; Selinka HC
    Virol J; 2006 Oct; 3():83. PubMed ID: 17014700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization sites of human papillomavirus-6 relate to virus attachment and entry phase in viral infection.
    Liu X; Chen J; Wang Z; Wang D; He M; Qian C; Song S; Chi X; Kong Z; Zheng Q; Wang Y; Yu H; Zhao Q; Zhang J; Li S; Gu Y; Xia N
    Emerg Microbes Infect; 2019; 8(1):1721-1733. PubMed ID: 31769733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional assessment and structural basis of antibody binding to human papillomavirus capsid.
    Zhang X; Li S; Modis Y; Li Z; Zhang J; Xia N; Zhao Q
    Rev Med Virol; 2016 Mar; 26(2):115-28. PubMed ID: 26676802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Naturally Occurring Variation in the Human Papillomavirus 58 Capsid Proteins on Recognition by Type-Specific Neutralizing Antibodies.
    Godi A; Martinelli M; Haque M; Li S; Zhao Q; Xia N; Cocuzza CE; Beddows S
    J Infect Dis; 2018 Oct; 218(10):1611-1621. PubMed ID: 29905865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies.
    Bishop B; Dasgupta J; Klein M; Garcea RL; Christensen ND; Zhao R; Chen XS
    J Biol Chem; 2007 Oct; 282(43):31803-11. PubMed ID: 17804402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies.
    Carpentier GS; Fleury MJ; Touzé A; Sadeyen JR; Tourne S; Sizaret PY; Coursaget P
    J Med Virol; 2005 Dec; 77(4):558-65. PubMed ID: 16254978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological analyses of human papillomavirus capsids.
    Giroglou T; Sapp M; Lane C; Fligge C; Christensen ND; Streeck RE; Rose RC
    Vaccine; 2001 Feb; 19(13-14):1783-93. PubMed ID: 11166904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.
    Combita AL; Touzé A; Bousarghin L; Christensen ND; Coursaget P
    J Virol; 2002 Jul; 76(13):6480-6. PubMed ID: 12050360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
    Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
    J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro.
    Wei M; Wang D; Li Z; Song S; Kong X; Mo X; Yang Y; He M; Li Z; Huang B; Lin Z; Pan H; Zheng Q; Yu H; Gu Y; Zhang J; Li S; Xia N
    Emerg Microbes Infect; 2018 Sep; 7(1):160. PubMed ID: 30254257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
    Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
    Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36.
    Bywaters SM; Brendle SA; Tossi KP; Biryukov J; Meyers C; Christensen ND
    Viruses; 2017 Nov; 9(11):. PubMed ID: 29125554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitopes on Human Papillomavirus 16.
    Guan J; Bywaters SM; Brendle SA; Ashley RE; Makhov AM; Conway JF; Christensen ND; Hafenstein S
    Viruses; 2017 Dec; 9(12):. PubMed ID: 29211035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain.
    Ludmerer SW; McClements WL; Wang XM; Ling JC; Jansen KU; Christensen ND
    Virology; 2000 Jan; 266(2):237-45. PubMed ID: 10639310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.
    Kalnin K; Chivukula S; Tibbitts T; Yan Y; Stegalkina S; Shen L; Cieszynski J; Costa V; Sabharwal R; Anderson SF; Christensen N; Jagu S; Roden RBS; Kleanthous H
    Vaccine; 2017 Sep; 35(37):4942-4951. PubMed ID: 28778613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for the shared neutralization mechanism of three classes of human papillomavirus type 58 antibodies with disparate modes of binding.
    He M; Chi X; Zha Z; Li Y; Chen J; Huang Y; Huang S; Yu M; Wang Z; Song S; Liu X; Wei S; Li Z; Li T; Wang Y; Yu H; Zhao Q; Zhang J; Zheng Q; Gu Y; Li S; Xia N
    J Virol; 2021 Mar; 95(7):. PubMed ID: 33472937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.